

PROVIDER APPEAL TEMPLATE FOR OLUMIANT

[Your Name]
[Your Title]
[Your Address]
[City, State, Zip Code]
[Phone Number]
[Email Address]
[Date]

Claims Department
[Insurance Company Name]
[Insurance Company Address]
[City, State, Zip Code]

Dear Claims Review Team,

Re: Request for Coverage of Olumiant (baricitinib) for Treatment of Alopecia Areata

I am writing to formally request that [Insurance Company Name] reconsider its decision to deny coverage for Olumiant (baricitinib) for my patient, [Patient's Full Name], who has been diagnosed with alopecia areata. As you are aware, alopecia areata is an autoimmune disease that causes unpredictable and often distressing hair loss, and it can significantly impact the mental and emotional well-being of those affected. After careful evaluation and treatment consideration, Olumiant has been prescribed as an appropriate therapeutic option for this patient's condition.

Medical Necessity of Olumiant for Alopecia Areata

Alopecia areata is a chronic, autoimmune disease in which the immune system mistakenly attacks hair follicles, leading to hair loss. Treatment options have been limited, and many existing therapies have suboptimal efficacy, side effects, or both.

[Include patient's previous treatments/results here]

Olumiant is the first of three Janus kinase inhibitors (JAK inhibitor) to receive FDA approval for severe alopecia areata. It is indicated for patients 18 years of age and older, and offers an effective treatment for managing alopecia areata. [Recent clinical trials](#) and studies have demonstrated Olumiant's ability to promote hair regrowth in patients with moderate to severe alopecia areata.

This evidence supports the fact that Olumiant is not only a safe and effective treatment for alopecia areata but also represents a medically necessary option for patients who have not responded well to other therapies. Additionally, by improving the quality of life for patients and

reducing the psychological burden of alopecia areata, Olumiant may help mitigate the long-term healthcare costs associated with mental health treatment and therapy.

The treatment plan for [Patient's Full Name] includes Olumiant as a medically necessary intervention to control the progression of alopecia areata, encourage hair regrowth, and improve the patient's quality of life. Given the distressing nature of this condition, the psychological impact of visible hair loss, and the failure of prior treatment options, Olumiant represents a necessary and appropriate option for achieving optimal therapeutic outcomes.

In light of the substantial clinical evidence supporting Olumiant's efficacy and safety profile, as well as its potential to improve both the physical and mental health of patients with alopecia areata, I respectfully request that [Insurance Company Name] reconsider its denial of coverage for this treatment. Given the unique challenges posed by alopecia areata, Olumiant offers a medically necessary and effective option for managing this condition, and it is essential for improving the patient's quality of life.

Thank you for your time and consideration of this request. Please do not hesitate to contact me if you require any further information or clarification.

Sincerely,

[Your Name]

[Your Title]

[Your Contact Information]

Additional references:

[King, Brett, et al. "Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment." *American Journal of Clinical Dermatology* \(2025\): 1-12.](#)

[Senna, M., et al. "Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2." *Journal of the European Academy of Dermatology and Venereology* 38.3 \(2024\): 583-593.](#)

[Piraccini, Bianca M., et al. "Improvement in health-related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials." *JEADV Clinical Practice* 3.1 \(2024\): 242-248.](#)

[King, Brett, et al. "Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials." *British Journal of Dermatology* 188.2 \(2023\): 218-227.](#)